放疗联合低剂量替莫唑胺后序贯替莫唑胺与伊立替康治疗胶质母细胞瘤的2期研究:NRG Oncology RTOG 0420试验
这项单臂多机构2期试验评估新诊断胶质母细胞瘤患者同步放化疗后辅助替莫唑胺联合伊立替康12个月的毒性与疗效。170例入组、152例合格,联合方案血液学和胃肠道毒性高于预期,3/4级血液学毒性38%对比Stupp试验的14%。合格患者中位总生存16.9个月对比历史对照13.7个月(P=.03),但历史对照13.7个月不代表当前基准。
要点
- 辅助替莫唑胺联合伊立替康较预期毒性更高,3/4级血液学毒性38%对比Stupp试验14%。
- 合格患者中位总生存16.9个月对比历史对照13.7个月(P=.03),但历史对照不代表当前基准。
- 事后亚组分析提示RTOG递归分割分析3类患者总生存改善,但改善仅限于22例(合格患者的14%)。
核心结论
- 同步放化疗后替莫唑胺联合伊立替康12个周期较当时历史对照显著改善新诊断胶质母细胞瘤患者中位生存,但历史对照中位生存13.7个月不代表当前该人群基准。
- 与当前标准相比,治疗强化可延长总生存。
- 辅助替莫唑胺联合伊立替康较预期毒性更高。
研究设计与样本
- RTOG 04-20为单臂、多机构2期试验,旨在确定同步替莫唑胺和放疗后辅助替莫唑胺联合伊立替康12个周期的疗效和毒性,并与辅助替莫唑胺单药6个周期的历史对照比较。
- 共入组170例患者,其中152例合格。
- 早期中期分析后,辅助伊立替康剂量降至第1周期第1天和第5天100 mg/m2;若可耐受,伊立替康剂量在前3个周期内递增。
主要发现
- 辅助伊立替康联合替莫唑胺较预期毒性更高,联合方案血液学和胃肠道毒性发生率高于辅助替莫唑胺单药。
- 3/4级血液学毒性为38%,对比Stupp试验报告的14%。
- 所有合格患者中位总生存为16.9个月,对比历史对照的13.7个月(P=.03)。
- 事后亚组分析提示RTOG递归分割分析3类患者总生存改善,但改善仅限于22例患者(合格患者的14%)。
关键数值与推荐
- 3/4级血液学毒性:联合方案38%对比Stupp试验14%。
- 所有合格患者中位总生存:16.9个月对比历史对照13.7个月(P=.03)。
- 事后亚组分析提示RTOG递归分割分析3类患者总生存改善,但改善仅限于22例患者(合格患者的14%)。
- 早期中期分析后,辅助伊立替康剂量降至第1周期第1天和第5天100 mg/m2;若可耐受,伊立替康剂量在前3个周期内递增。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出历史对照中位生存13.7个月不代表当前该患者人群的基准。
- 事后亚组分析提示的RTOG递归分割分析3类患者总生存改善仅限于22例患者(合格患者的14%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the toxicity and efficacy of adjuvant temozolomide (TMZ) and irinotecan (CPT-11) for 12 months after concurrent chemoradiation in patients with newly diagnosed glioblastoma (GBM). METHODS AND MATERIALS: Trial RTOG 04-20, a single-arm, multi-institutional phase 2 trial, was designed to determine the efficacy and toxicity of concomitant TMZ and radiation therapy (RT) followed by adjuvant TMZ combined with CPT-11 given for 12 cycles compared with historical controls of adjuvant TMZ alone given for 6 cycles. RESULTS: A total of 170 patients were enrolled, 152 of whom were eligible. Adjuvant CPT-11 combined with TMZ was more toxic than expected. A higher rate of hematologic and gastrointestinal toxicities was more frequently noted with the combination regimen compared with adjuvant TMZ alone. Grade 3/4 hematologic toxicity was 38% compared with 14% reported in the Stupp trial. After an early interim analysis, the adjuvant CPT-11 dose was reduced to 100 mg/m2 on days 1 and 5 for the first cycle. CPT-11 dose escalation proceeded over the first 3 cycles if tolerated. Median overall survival for all eligible patients was 16.9 months compared with 13.7 months of the historical control (P = .03). Post hoc subgroup analysis suggested an improvement in overall survival for patients with Radiation Therapy Oncology Group recursive partitioning analysis class 3, although improvement was limited to 22 patients (14% of eligible patients). CONCLUSIONS: Although irinotecan and TMZ for 12 cycles given after chemoradiation for patients with newly diagnosed glioblastoma significantly improved median survival compared with historical control data at the time the study was conducted, the historical control median survival time of 13.7 months does not represent the current benchmark for this patient population. Treatment intensification does prolong overall survival compared with the current standard.
引用
- Lieberman FS, Wang M, Robins HI, et al. Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. Int J Radiat Oncol Biol Phys. 2018. PMID: 30496882. doi:10.1016/j.ijrobp.2018.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。